Executive Summary
- •ONWARD Medical announced the first implant in a feasibility study testing its ARC-IM system to restore mobility after spinal cord injuries.
- •The EIGER trial will enroll up to 12 participants with subacute or chronic injuries in Switzerland.
- •The data will directly inform the design of a future pivotal study required for market approval.
Community Sentiment
Key Developments & Data
ONWARD Medical announced the first implant procedure in its EIGER clinical feasibility study evaluating the investigational ARC-IM System.
The trial aims to enroll up to 12 participants in Switzerland to assess the recovery of standing and walking after a spinal cord injury.
The company’s ARC-IM System consists of an implanted neurostimulator and a lumbar lead designed to precisely activate specific spinal circuits.
ONWARD’s proprietary ARC Therapy has previously received 10 Breakthrough Device Designations from the US FDA.
"The EIGER study is an important next step in our drive to restore mobility after spinal cord injury." — Dave Marver
Zubiqo Strategic Assessment
Primary Impact
Patients with severe spinal cord injuries and the broader neurotechnology medical device sector.
Strategic Shift
The continued transition of advanced neuromodulation systems from theoretical research into targeted clinical feasibility trials for mobility restoration.
The Ripple Effect
Successful preliminary safety data from this 12-patient cohort will likely accelerate the timeline for a larger pivotal trial required for commercial approval.
This intelligence assessment is generated by Zubiqo's AI for informational purposes only.
Intelligence Quality Rating
Grade this brief: Slide & release to submit rating, or tap a preset.
🔥High Impact75/100
Slide & release to voteImmune to accidental scroll
Zubiqo Briefing
The daily signal, delivered every weekday.
A concise weekday briefing on AI, technology and business. Zero PR fluff.
Subscribe directly on Substack
Subscription completes on Substack • Free • 1-click unsubscribe anytime
✓ Free on Substack✓ Official Substack enrollment✓ 1-click unsubscribe
